INHIBITION OF ANTI-IGE INDUCED SKIN-RESPONSE IN NORMALS BY FORMOTEROL, A NEW BETA-2-ADRENOCEPTOR AGONIST, AND TERBUTALINE .1. DOSE-RESPONSE RELATION AND DURATION OF EFFECT ON THE EARLY WHEAL AND FLARE RESPONSE

被引：14

作者：

GRONNEBERG, R ^{[1
]}

ZETTERSTROM, O ^{[1
]}

机构：

[1] KAROLINSKA HOSP,DEPT THORAC MED,ALLERGOL SECT,S-10401 STOCKHOLM 60,SWEDEN

来源：

ALLERGY | 1990年 / 45卷 / 05期

关键词：

anti‐IgE; flare response; formoterol; histamine; mast cell; terbutaline; wheal response; β‐agonist;

D O I：

10.1111/j.1398-9995.1990.tb00508.x

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

The intention of the present study was to compare formoterol and terbutaline regarding ability to inhibit immediate wheal and Hare responses (WFR) to antihuman IgE with focus on the duration of anti‐WFR action. Formoterol is a novel β2‐adrenergic agonist with a prolonged duration of bronchodilation capacity after inhalation. The drugs injected intradermally 2 min prior to challenge with anti‐IgE in volunteers produced a dose‐dependent inhibition of the WFR in the range 1pg–100ng (formoterol) and Ing‐1μg (terbutaline). Formoterol was 70 times (flare) and 25 times (wheal) more potent (ID40) than terbutaline on a weight basis. The duration of the anti‐WFR action for formoterol, injected in a 25 times lower dose than terbutaline, was significantly longer, namely > 24 h versus 8 h for terbutaline. The histanune induced wheal reaction was attenuated by 15% and 25% by terbutaline and formoterol, respectively. The results indicate a higher β2‐receptor activity for formoterol with respect to inhibition of IgE‐dependent mast cell mediator release in addition to an anti‐leak effect exerted by both drugs. The prolonged duration of antagonistic effect by formoterol on the WFR to anti‐IgE might be due to the lipophilic property of the drug, with an expected higher retention of formoterol at the target tissue compared with the more hydrophilic compound terbutaline. Copyright © 1990, Wiley Blackwell. All rights reserved

引用

页码：334 / 339

页数：6

共 14 条

[11] Persson CGA, 1985, HDB INFLAMMATION, V5, P61
[12] SUBRAMANIAN N, 1986, ARZNEIMITTEL-FORSCH, V36-1, P502
[13] SYBRECHT G, 1988, 12TH INT S HELD WORL, P1
[14] TING S, 1983, J ALLERGY CLIN IMMUN, V71, P437, DOI 10.1016/0091-6749(83)90458-X

← 1 2 →